{"id":232856,"date":"2026-03-09T07:08:34","date_gmt":"2026-03-09T12:08:34","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/preventing-breast-cancer-resistance-to-cdk4-6-inhibitors-using-genomic-findings"},"modified":"2026-03-09T07:08:34","modified_gmt":"2026-03-09T12:08:34","slug":"preventing-breast-cancer-resistance-to-cdk4-6-inhibitors-using-genomic-findings","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/preventing-breast-cancer-resistance-to-cdk4-6-inhibitors-using-genomic-findings","title":{"rendered":"Preventing breast cancer resistance to CDK4\/6 inhibitors using genomic findings"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/preventing-breast-cancer-resistance-to-cdk4-6-inhibitors-using-genomic-findings.jpg\"><\/a><\/p>\n<p>Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4\/6 inhibitors. This finding, <a href=\"https:\/\/www.nature.com\/articles\/s41586-026-10197-0\" target=\"_blank\">published<\/a> in <i>Nature<\/i>, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor\u2019s genetic profile.<\/p>\n<p>\u201cThis represents a major advance in understanding and predicting cancer behavior in response to treatment,\u201d says physician-scientist Pedram Razavi, MD, Ph.D., who led the study with physician-scientist Sarat Chandarlapaty, MD, Ph.D. The study\u2019s first author was Anton Safonov, MD, a physician-scientist in the MSK Breast Translational Program.<\/p>\n<p>\u201cTo our knowledge, this is the first example showing that a complete genomic analysis of breast cancer, including both inherited and tumor-specific alterations, can predict the precise biological mechanism of resistance before therapy even begins,\u201d Dr. Razavi adds.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4\/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor\u2019s genetic profile. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-232856","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=232856"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232856\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=232856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=232856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=232856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}